These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 19948277)

  • 1. Verteporfin photodynamic therapy cohort study: report 2: clinical measures of vision and health-related quality of life.
    Reeves BC; Langham J; Walker J; Grieve R; Chakravarthy U; Tomlin K; Carpenter J; Guerriero C; Harding SP;
    Ophthalmology; 2009 Dec; 116(12):2463-70. PubMed ID: 19948277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Verteporfin photodynamic therapy cohort study: report 1: effectiveness and factors influencing outcomes.
    Harding SP; Tomlin K; Reeves BC; Langham J; Walker J; Carpenter J; Grieve R; Patton WP; Muldrew KA; Peto T; Chakravarthy U;
    Ophthalmology; 2009 Dec; 116(12):e1-8. PubMed ID: 19948275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Verteporfin photodynamic therapy cohort study: report 3: cost effectiveness and lessons for future evaluations.
    Grieve R; Guerriero C; Walker J; Tomlin K; Langham J; Harding S; Chakravathy U; Carpenter J; Reeves BC;
    Ophthalmology; 2009 Dec; 116(12):2471-77.e1-2. PubMed ID: 19948278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Full macular translocation (FMT) versus photodynamic therapy (PDT) with verteporfin in the treatment of neovascular age-related macular degeneration: 2-year results of a prospective, controlled, randomised pilot trial (FMT-PDT).
    Lüke M; Ziemssen F; Völker M; Altpeter E; Beutel J; Besch D; Bartz-Schmidt KU; Gelisken F
    Graefes Arch Clin Exp Ophthalmol; 2009 Jun; 247(6):745-54. PubMed ID: 19214552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baseline clinical measures and early response predict success in verteporfin photodynamic therapy for neovascular age-related macular degeneration.
    García-Fiñana M; Murjaneh S; Mahmood S; Harding SP
    Eye (Lond); 2010 Jul; 24(7):1213-9. PubMed ID: 20075972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Verteporfin photodynamic therapy for neovascular age-related macular degeneration: cohort study for the UK.
    Reeves BC; Harding SP; Langham J; Grieve R; Tomlin K; Walker J; Guerriero C; Carpenter J; Patton WP; Muldrew KA; Peto T; Chakravarthy U
    Health Technol Assess; 2012; 16(6):i-xii, 1-200. PubMed ID: 22348600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vision-related function after low-dose transpupillary thermotherapy versus photodynamic therapy for neovascular age-related macular degeneration.
    Odergren A; Algvere PV; Seregard S; Libert C; Kvanta A
    Acta Ophthalmol; 2010 Jun; 88(4):426-30. PubMed ID: 20597872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vision-related function after ranibizumab treatment by better- or worse-seeing eye: clinical trial results from MARINA and ANCHOR.
    Bressler NM; Chang TS; Suñer IJ; Fine JT; Dolan CM; Ward J; Ianchulev T;
    Ophthalmology; 2010 Apr; 117(4):747-56.e4. PubMed ID: 20189654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved vision-related function after ranibizumab vs photodynamic therapy: a randomized clinical trial.
    Bressler NM; Chang TS; Fine JT; Dolan CM; Ward J;
    Arch Ophthalmol; 2009 Jan; 127(1):13-21. PubMed ID: 19139332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group.
    Arch Ophthalmol; 1999 Oct; 117(10):1329-45. PubMed ID: 10532441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Responsiveness of NEI VFQ-25 to changes in visual acuity in neovascular AMD: validation studies from two phase 3 clinical trials.
    Suñer IJ; Kokame GT; Yu E; Ward J; Dolan C; Bressler NM
    Invest Ophthalmol Vis Sci; 2009 Aug; 50(8):3629-35. PubMed ID: 19255158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Observational prospective study of the effectiveness in routine clinical practice of verteporfin photodynamic therapy in patients with neovascular age-related macular degeneration.
    Murjaneh S; García-Fiñana M; Mahmood S; Lenfestey PM; Taylor SA; Pearce IA; Briggs MC; Heimann H; Harding SP
    Br J Ophthalmol; 2009 Apr; 93(4):468-73. PubMed ID: 19074914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Verteporfin photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration.
    Kaiser PK; ; Boyer DS; Garcia R; Hao Y; Hughes MS; Jabbour NM; Kaiser PK; Mieler W; Slakter JS; Samuel M; Tolentino MJ; Roth D; Sheidow T; Strong HA
    Ophthalmology; 2009 Apr; 116(4):747-55, 755.e1. PubMed ID: 19243834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of early retreatment with the standard regimen in verteporfin therapy of neovascular age-related macular degeneration.
    Michels S; Wachtlin J; Gamulescu MA; Heimann H; Prünte C; Inhoffen W; Krebs I; Schmidt-Erfurth U
    Ophthalmology; 2005 Dec; 112(12):2070-5. PubMed ID: 16225928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) in age-related macular degeneration.
    Orr P; Rentz AM; Margolis MK; Revicki DA; Dolan CM; Colman S; Fine JT; Bressler NM
    Invest Ophthalmol Vis Sci; 2011 May; 52(6):3354-9. PubMed ID: 21282568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial.
    Azab M; Boyer DS; Bressler NM; Bressler SB; Cihelkova I; Hao Y; Immonen I; Lim JI; Menchini U; Naor J; Potter MJ; Reaves A; Rosenfeld PJ; Slakter JS; Soucek P; Strong HA; Wenkstern A; Su XY; Yang YC;
    Arch Ophthalmol; 2005 Apr; 123(4):448-57. PubMed ID: 15824216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of photodynamic therapy for age related macular degeneration upon subjective vision related quality of life.
    Hewitt AW; Jeganathan VS; Kidd JE; Pesudovs K; Verma N
    Graefes Arch Clin Exp Ophthalmol; 2006 Aug; 244(8):972-7. PubMed ID: 16411103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vision-related quality of life in patients with bilateral severe age-related macular degeneration.
    Cahill MT; Banks AD; Stinnett SS; Toth CA
    Ophthalmology; 2005 Jan; 112(1):152-8. PubMed ID: 15629836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2.
    Bressler NM;
    Arch Ophthalmol; 2001 Feb; 119(2):198-207. PubMed ID: 11176980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Age-Related Macular Degeneration and Quality of Life in Latinos: The Los Angeles Latino Eye Study.
    Choudhury F; Varma R; Klein R; Gauderman WJ; Azen SP; McKean-Cowdin R;
    JAMA Ophthalmol; 2016 Jun; 134(6):683-90. PubMed ID: 27124819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.